Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Mediterranean-Ketogenic diet protect the gut in Parkinson's?

NCT ID NCT05469997

Symptom relief Sponsor: University of British Columbia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a modified Mediterranean-ketogenic diet in 52 people with Parkinson's disease to see if it is safe for their gut microbiome. The diet limits carbs and emphasizes healthy fats and lean proteins. Researchers measured gut inflammation and other markers to check for any harm, aiming to find a diet that supports gut health without causing problems.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Mediterranean-Ketogenic Diet
What this could lead to
If successful, this diet could offer a safe way for Parkinson's patients to manage gut symptoms without disrupting their gut microbiome.
What could go wrong
This is a small, completed safety study with only 52 participants, so results may not apply to everyone. Dietary changes can be hard to maintain and may not improve Parkinson's symptoms directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

52 people

The number who actually took part.

Started

Mar 2023

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 40-85 years * PD diagnosis based on Movement Disorder Society (MDS) criteria \[52\] * Hoehn \& Yahr score of 1 to 3 * On stable dopaminergic medication for at least one month Exclusion Criteria: * Atypical parkinsonism * Medical or psychiatric conditions that would prevent full participation in the nutrition intervention * Significant dysphagia * Diabetes on insulin * Anti-coagulation on warfarin * Inflammatory bowel disease * Dementia defined by Montreal Cognitive Assessment (MoCA) Scores of less than 21 * Inability to fill in electronic questionnaires or understand study instructions * Use of immunomodulatory agents * Probiotic use in the last 4 weeks (except for dietary sources such as yoghurt, kefir etc.), or antibiotic use in the last 3 months prior to the trial * Use of MCT oil or on ketogenic diet in last 8 weeks prior to the trial * Allergic to MCT oil, coconut oil, or coconut

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson disease

Contacts and locations

Locations

  • Djawad Mowafaghian Centre for Brain Health

    Vancouver, British Columbia, V6T 1Z3, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.